Psychotropic medication during endocrine treatment for breast cancer

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1533-1540

  De Bock, Geertruida H ^a   Musters, Regina F ^b   Bos, H Jens ^b   Schröder, Caroline P ^a   Mourits, Marian J E ^a   De Jong Van Den Berg, Lolkje T W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Breast cancer survivor; Depression; Endocrine treatment; Psychotropic medication; Quality of life

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANASTROZOLE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; DIAZEPAM; EXEMESTANE; FULVESTRANT; HYPNOTIC SEDATIVE AGENT; LETROZOLE; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM; MIRTAZAPINE; NITRAZEPAM; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; TAMOXIFEN; TEMAZEPAM; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISTRESS SYNDROME; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; TIME FACTORS; YOUNG ADULT;

EID: 84863984552     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1242-5     Document Type: Article

References (25)

1. Integraal Kanker Centrum. Available at http://www.ikcnet.nl.Accessed May 2009
2. Carlson RW, Hudis CA, Pritchard KI (2006) National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 4: 971-979
3. Goel S, Sharma R, Hamilton A, Beith J (2009) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 4: CD004562
4. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343-353
5. Ingle JN (2006) Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res 12: 1031s-1036s
6. Gibson L, Lawrence D, Dawson C, Bliss J (2009) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 4: CD003370
7. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687-1717
8. Kornblith AB, Ligibel J (2003) Psychosocial and sexual functioning of survivors of breast cancer. Semin Oncol 39: 799-813
9. Buijs C, de Vries EG, Mourits MJ, Willemse PH (2008) The influence of endocrine treatments for breast cancer on healthrelated quality of life. Cancer Treat Rev 34: 640-655
10. IADB drug use research. Available at http://www.iadb.nl. Accessed Aug 2009
11. Farmacotherapeutische kompas. Available at http://www.fk.cvz.nl/ Accessed Jun 2009
12. WHO Collaborating Centre for Drugs Statistics Methodology. ATC/DDD index 2008. Available at http://www.whocc.no/atcddd. Accessed May 2009
13. Monster TBM, Janssen WM, de Jong PE, de Jong-van den Berg LTW (2002) Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 11: 379-384
14. Jabaaij L (2002) Top 10: diagnoses en voorschrijven. Huisarts en Wetenschap 45: 57 [In Dutch]
15. Lueboonthavatchai P (2007) Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai 90: 2164-2174
16. Mehnert A, Koch U (2008) Psychological comorbidity and healthrelated quality of life and its association with awareness utilization, and need for psychosocial support in a cancer based sample of long-term breast cancer survivors. J Psychosom Res 64: 383-391
17. Montazeri A (2008) Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 27: 32
18. Karakoyun-Celik O, Gorken I, Sahin S, Orcin E, Alanyali H, Kinay M (2010) Depression and anxiety levels in woman under follow-up for breast cancer: relationship to coping with cancer and quality of life. Med Oncol 27: 108-113
19. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. Brit Med J 330: 702
20. Reich M, Lesur A, Perdrizet-Chevallier C (2008) Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 110: 9-17
21. Buijs C, Mom CH, Willemse PH, Marike Boezen H, Maurer JM, Wymenga AN, de Jong RS, Nieboer P, de Vries EG, Mourits MJ (2009) Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a doubleblind, randomized cross-over study. Breast Cancer Res Treat 115: 573-580
22. Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J (2010) Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause 17: 889-891
23. Uzun S, Kozumplik O, Jakovljević M, Sedić B (2010) Side effects of treatment with benzodiazepines. Psychiatr Danub 22: 90-93
24. Kelly CM, Juurlink DN, Gomes T, Hua MD, Pritchard KI, Austin PC, Paszat LF (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Brit Med J 340: c693. doi: 10.1136/bmj
25. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28: 2768-2776